Commentary | Published:

Bringing safe and effective cell therapies to the bedside

Subjects

New rules to assess the safety and efficacy of human cell- and tissue-based products are the culmination of a multiyear, cooperative effort between the US government and the biotech industry.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Department of Health and Human Services, Food and Drug Administration. Human cells, tissues, and cellular and tissue-based; donor screening and testing; and related labeling. Fed. Regist. 70, 29949–29952 (2005). <http://reform.house.gov/UploadedFiles/FDA%20Regulation%2021%20CFR%201271.pdf>

  2. 2

    Department of Health and Human Services, Food and Drug Administration. Application of current statutory authorities to human somatic cell therapy products and gene therapy products, Docket 93N-0173. Fed. Regist. 58, 53248–53251 (1993). <http://www.fda.gov/cber/genadmin/fr101493.pdf>

Download references

Author information

Rights and permissions

To obtain permission to re-use content from this article visit RightsLink.

About this article

Further reading